AdvaMed Accel Webinar: NIH SBIR/STTR Funding Opportunities

Learn how the EY Clinical Trial Fast Lane solution helps jumpstart clinical trials in 45 to 60 working days through rapid performance of functional services, deep understanding of clinical trial operations, and more.

AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker upon the passage of a research and development expensing tax provision critical to medtech innovation in the House of Representatives.

Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today urged Congress to enact a research and development expensing tax provision critical to medtech innovation. The provision would delay a change requiring businesses to deduct their research and development expenses over five years, allowing immediate deduction.

Join us for a breakdown of the Chinese medical device market, to review the current regulatory requirements and pathways, and address I.P. protection in China for U.S. companies.

Following the introduction of the bipartisan American Innovation and Jobs Act in the U.S. Senate and its House companion the American Innovation and R&D Competitiveness Act, AdvaMed, the MedTech Association, called on lawmakers to quickly pass the legislation which would allow for small companies to deduct their research and development expenses in the year they are incurred. Currently, companies are required to deduct their expenses over the course of five years.

AdvaMed’s medtech priorities for the 118th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.

From MDUFA V and the major investments in semiconductor chip manufacturing in the CHIPS Act, to addressing global supply chain issues and supporting our AdvaMed Accel companies, 2022 was a year like no other.